Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Wien, Austria.
Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z.
Bone health and breast cancer are two connected subjects, because breast cancer patients have a higher prevalence of osteopenia/osteoporosis and reduced bone health parameters than healthy woman of the same age. Therefore, the positive effect of adjuvant bisphosphonate therapy plays an important role in breast cancer treatment. Several randomized trials have studied bisphosphonates in the adjuvant setting in postmenopausal woman and demonstrated their potential to prevent treatment-induced bone loss. The prevention of fractures and the subsequent preservation of patients' quality of life are important arguments for the use of adjuvant bisphosphonates in postmenopausal breast cancer patients. In addition, trials of adjuvant bone-targeted agents showed a reduction of recurrences in and outside bone and an improved outcome in patients treated with bisphosphonates.
骨骼健康与乳腺癌是两个相互关联的课题，因为乳腺癌患者的骨量减少/骨质疏松症患病率以及骨健康参数均高于同年龄健康女性。因此，辅助双膦酸盐治疗的积极作用在乳腺癌治疗中发挥着重要作用。一些随机临床试验已经研究了绝经后女性辅助双膦酸盐在辅助治疗中的作用，证实了它们预防治疗引起的骨丢失的潜力。预防骨折和随后维持患者的生活质量是绝经后乳腺癌患者使用辅助双膦酸盐的重要依据。此外，辅助骨靶向药物的临床试验显示，接受双膦酸盐治疗的患者的骨内和骨外复发减少，且结局得到改善。
